How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Pharma and Healthcare · Forecast 2027–2033
Nanoemulsions Market
- By Application: Pharmaceuticals, Cosmetics and Personal Care, Food and Beverages, Agriculture, Chemical Industry
- By Formulation Type: Oil-in-Water (O/W) Nanoemulsions, Water-in-Oil (W/O) Nanoemulsions, Bicontinuous Nanoemulsions
- By Method of Preparation: High-Energy Methods, Low-Energy Methods
- By Droplet Size: 20-100 nm, 100-200 nm, Above 200 nm
- By Surfactant Type: Nonionic Surfactants, Anionic Surfactants, Cationic Surfactants, Zwitterionic Surfactants
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Projected to reach $X,XXX.XM by 2033 on sustained demand. Market Outlook →
- 03 Growth - X.XX% CAGR across 2027–2033, with the full year-by-year model inside. Market Outlook →
- 04 Leading segment - Pharmaceuticals leads By Application at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 287 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.173 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.181 →
Full report · locked preview
Everything inside the Nanoemulsions Market report
A complete, evidence-based study - 12 chapters and 120 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Application 5
Formulation Type 3
Method of Preparation 2
Droplet Size 3
Surfactant Type 4
Companies profiled
BASF SE
Croda International Plc
Gattefossé
Evonik Industries AG
Dow Inc.
Lubrizol Corporation
Nippon Oil Corporation
AstraZeneca Plc
L'Oréal S.A.
Cognis GmbH (a BASF company)
Sonoco Products Company
Jeen International Corporation
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →BASF SE
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Croda International Plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Gattefossé
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Evonik Industries AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Dow Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Lubrizol Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Nippon Oil Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →AstraZeneca Plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →L'Oréal S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Cognis GmbH (a BASF company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Sonoco Products Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Jeen International Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Nanoedge LLC
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Nanoshel LLC
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Sasol Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →
Global · 2025–2033
$4,458M by 2033 · 10.9% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Pharmaceuticals28.9
- Cosmetics and Personal Care18.3
- Food and Beverages22.1
- Agriculture18.5
- Chemical Industry12.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$642.4M → $1,326M · 9.5%
Europe$447.7M → $987.2M · 10.4%
Asia Pacific$408.8M → $1,037M · 12.3%
Latin America$253.1M → $641.0M · 12.3%
Middle East and Africa$194.7M → $468.1M · 11.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.862026
10.882027
10.892028
10.902029
10.902030
10.932031
10.942032
10.942033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- BASF SE13.6
- Croda International Plc21.4
- Gattefossé6.5
- Evonik Industries AG12.2
- Dow Inc.8.5
- Lubrizol Corporation9.9
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Application29.7%
Formulation Type19.5%
Method of Preparation13.6%
Droplet Size18.7%
Surfactant Type18.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America29.7
- Europe22.1
- Asia Pacific23.3
- Latin America14.4
- Middle East and Africa10.5
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| BASF SE | 97 | 83 | 77 | 78 | 93 | 81 | 85 |
| Croda International Plc | 68 | 84 | 84 | 84 | 79 | 93 | 82 |
| Gattefossé | 71 | 79 | 66 | 66 | 66 | 82 | 72 |
| Evonik Industries AG | 57 | 68 | 63 | 57 | 74 | 64 | 64 |
| Dow Inc. | 76 | 61 | 56 | 64 | 57 | 61 | 63 |
| Lubrizol Corporation | 70 | 62 | 58 | 52 | 63 | 49 | 59 |
| Nippon Oil Corporation | 47 | 41 | 50 | 64 | 56 | 44 | 50 |
| AstraZeneca Plc | 52 | 40 | 49 | 49 | 48 | 39 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- BASF SE
- Croda International Plc
- Gattefossé
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| BASF SE | ✓ | ✓ | ◐ | ◐ | ✓ | ✓ |
| Croda International Plc | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Gattefossé | ◐ | ◐ | ◐ | ◐ | − | ◐ |
| Evonik Industries AG | ◐ | ◐ | ✓ | − | ◐ | ◐ |
| Dow Inc. | ◐ | − | ◐ | − | ◐ | ◐ |
| Lubrizol Corporation | ✓ | ◐ | − | − | ◐ | − |
| Nippon Oil Corporation | − | − | − | ◐ | ◐ | − |
| AstraZeneca Plc | ◐ | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1BASF SE85
2Croda International Plc82
3Gattefossé72
4Evonik Industries AG64
5Dow Inc.63
6Lubrizol Corporation59
7Nippon Oil Corporation50
8AstraZeneca Plc46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
BASF SECroda International Plc
Challenger1
Strong scale, closing on the leaders.
Gattefossé
Contender3
Focused players with pockets of strength.
Evonik Industries AGDow Inc.Lubrizol Corporation
Niche2
Specialists in a single segment or region.
Nippon Oil CorporationAstraZeneca Plc
Go-to-market strategy
Land Application in North America, then scale across Nanoemulsions Market — a $403M beachhead inside a $7.94B market.
Beachhead (SOM)$403Mobtainable near-term
Serviceable (SAM)$2.84Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
Pharmaceuticals
Best fit — highest urgency & budget in Application.
Economic buyer78 fit
Cosmetics and Personal Care
Strong fit — clear ROI and a fast path to value.
End user67 fit
Food and Beverages
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Application in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Formulation Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Method of Preparation
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel30%
Digital / self-serve21%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Application leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Nanoemulsions Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified21%
Evaluation14%
Closed-won7%
$16.1KCAC
$71KLTV
4.4:1LTV : CAC
< 5 moCAC payback
Investment thesis
Nanoemulsions Market is a durable-growth opportunity — $2.99B by 2033, compounding at 9.3%.
TAM · 2025$1.47Btoday
TAM · 2033$2.99Bforecast
CAGR9.3%2027–2033
Cumulative$19.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.99BTotal addressable market
SAM$1.13BServiceable available market
SOM$219MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.3% CAGR
Demand compounds through 2033, outpacing GDP across Application.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Application moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.99BLarge & growingTAM by 2033 at 9.3% CAGR
$1.13BServiceable nowreachable with today’s model
$219MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.34BBear6.0% CAGR
$2.99BBase9.3% CAGR
$3.83BBull12.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Formulation Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Nanoemulsions Market — a $3.95B market by 2033. Plan: grow share from 8.0% to 16.4%.
Market size · 2033$3.95Btotal addressable
Market CAGR3.4%2027–2033
Target share16.4%from 8.0% today
Revenue ambition$648Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.0% | 16.4% | Behind |
| Revenue | $338M | $648M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 38.0% | 38.3% | On track |
| Customer retention | 87.0% | 92.4% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Application
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Formulation Type capability
A defensible second engine — invest in Formulation Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Application share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Formulation Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $70M capacity & capability investment
- Greenlight bolt-on M&A in Formulation Type
- Authorise North America expansion plan
- Fund R&D program for Application leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeAhead
- Execution & talentOn track
Sales deck · value proposition
Win the Nanoemulsions Market conversation — a $1.80B market you can size, segment and defend in minutes.
Market size · 2033$1.80Btotal opportunity
Growth11.5%CAGR to 2033
Addressable buyers1,617+accounts in scope
Typical ROI6.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Application
Goal Grow share in Application
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.9×return on cost, year one
< 3 mopayback period
$90K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
BASF SECroda International PlcGattefosséEvonik Industries AGDow Inc.Lubrizol CorporationNippon Oil CorporationAstraZeneca Plc+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Nanoemulsions Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Nanoemulsions Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Pharma and Healthcare · scroll →Opioid Anesthetics Market
Market size, share, segmentation and regional forecast.
$12.0B by 2032 · 10.51% CAGR
View reportBiosimilar Monoclonal Antibodies Market
Market size, share, segmentation and regional forecast.
$4.9B by 2033 · 9.38% CAGR
View reportAnti-Retroviral Drugs Market
Market size, share, segmentation and regional forecast.
$8.1B by 2032 · 4.78% CAGR
View reportBone Morphogenetic Proteins Market
Market size, share, segmentation and regional forecast.
$12.5B by 2032 · 5.03% CAGR
View reportCellulite Treatment Market
Market size, share, segmentation and regional forecast.
$7.6B by 2033 · 10.27% CAGR
View reportOral Anti-Diabetic Drug Market
Market size, share, segmentation and regional forecast.
$10.1B by 2031 · 10.30% CAGR
View reportCutaneous Fribrosis Treatment Market
Market size, share, segmentation and regional forecast.
$9.5B by 2031 · 6.87% CAGR
View reportSaline Laxatives Market
Market size, share, segmentation and regional forecast.
$2.0B by 2032 · 7.36% CAGR
View reportNebulizers Market
Market size, share, segmentation and regional forecast.
$3.9B by 2032 · 7.40% CAGR
View reportOxytocic Pharmaceuticals Market
Market size, share, segmentation and regional forecast.
$9.3B by 2032 · 9.95% CAGR
View reportHypertension Drugs Market
Market size, share, segmentation and regional forecast.
$3.3B by 2031 · 9.88% CAGR
View reportHepatitis C Drugs Market
Market size, share, segmentation and regional forecast.
$12.5B by 2031 · 3.61% CAGR
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.